Anavex Successfully Completes a Phase 1 Clinical Trial for ANAVEX 2-73

Hoboken, NJ — November 14, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced the successful completion of its Phase 1 single ascending dose (SAD) clinical trial of ANAVEX 2-73, the company’s lead drug candidate for the treatment of Alzheimer’s Disease (AD).  ANAVEX 2-73 is the first of a new class of oral…